H Lundbeck and Otsuka Pharmaceutical have expanded their alliance and entered into collaboration for the development and commercialisation of Lu AE58054 for the treatment of Alzheimer’s disease.

As part of the alliance, Lundbeck has given Otsuka co-development and co-commercialisation rights to Lu AE58054, a selective 5HT6 receptor antagonist, in the US, Canada, East Asia and major European countries.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Otsuka Pharmaceutical president and representative director Taro Iwamoto said the global collaboration between Otsuka and Lundbeck continues to grow stronger with the addition of Lu AE58054.

"As part of the alliance, Lundbeck has given Otsuka co-development and co-commercialisation rights to Lu AE58054, a selective 5HT6 receptor antagonist, in the US, Canada, East Asia and major European countries."

"Not only does the product further enhance the synergy between the companies as we work together to bring to the market solutions for better health, Lu AE58054 is a potentially promising development in a very difficult disease area," Iwamoto said.

According to the terms of the deal, Lundbeck will earn an initial payment of $150m and be eligible for $675m in regulatory and sales milestones from Otsuka.

The sales, development and commercialisation costs will be shared by both the companies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Further financial details of the agreement were not disclosed.

Lundbeck president and chief executive officer Ulf Wiinberg said; "Together, Otsuka and Lundbeck with their development capabilities, commercial experience and geographical reach will provide a solid foundation in the development of Lu AE58054."

The pivotal clinical programme, consisting of several studies with Lu AE58054, is scheduled for commencement in 2013.

The first Phase III study will enrol patients with mild-to-moderate Alzheimer’s disease to test Lu AE58054 as adjunct treatment to donepezil.